* Inhibikase Therapeutics Inc IKT.OQ reported a quarterly
adjusted loss of 65 cents per share for the quarter ended
September 30, higher than the same quarter last year, when the
company reported EPS of -86 cents. The mean expectation of
two analysts for the quarter was for a loss of 37 cents per
share. Wall Street expected results to range from -68 cents
to -6 cents per share.
* Reported revenue was zero; analysts expected zero.
* Inhibikase Therapeutics Inc's reported EPS for the quarter
was a
loss of 65 cents.
* The company reported a quarterly loss of $5.78 million.
* Inhibikase Therapeutics Inc shares had risen by 86.2% this
quarter and gained 90.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 49% in
the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Inhibikase
Therapeutics Inc is 6.50
This summary was machine generated from LSEG data November 14 at
08:57 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.37 -0.65 Missed
Jun. 30 2024 -0.67 -0.66 Beat
Mar. 31 2024 -0.79 -0.73 Beat
Dec. 31 2023 -0.85 -0.64 Beat